Research Analysts Issue Forecasts for Dr. Reddy’s Laboratories Limited’s Q2 2025 Earnings (NYSE:RDY)

Posted by on Jun 26th, 2023

Dr. Reddy’s Laboratories Limited (NYSE:RDY – Get Rating) – Investment analysts at Zacks Research boosted their Q2 2025 earnings estimates for Dr. Reddy’s Laboratories in a research note issued on Thursday, June 22nd. Zacks Research analyst E. Bagri now forecasts that the company will post earnings per share of $0.90 for the quarter, up from their prior estimate of $0.87. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $3.40 per share.

RDY has been the subject of several other research reports. Bank of America raised Dr. Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a research report on Friday, March 17th. Sanford C. Bernstein downgraded shares of Dr. Reddy’s Laboratories from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 18th. Barclays raised their price target on shares of Dr. Reddy’s Laboratories from $67.00 to $70.00 in a research note on Thursday, June 1st. Finally, StockNews.com began coverage on shares of Dr. Reddy’s Laboratories in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $70.00.

Dr. Reddy’s Laboratories Trading Up 0.8 %

Shares of Dr. Reddy’s Laboratories stock opened at $61.00 on Monday. Dr. Reddy’s Laboratories has a 1 year low of $49.79 and a 1 year high of $61.53. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.41 and a quick ratio of 1.84. The business has a 50 day moving average price of $57.86 and a 200 day moving average price of $55.57. The company has a market capitalization of $10.16 billion, a P/E ratio of 18.32, a P/E/G ratio of 2.40 and a beta of 0.50.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Rating) last issued its quarterly earnings data on Wednesday, May 10th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.13. Dr. Reddy’s Laboratories had a net margin of 18.38% and a return on equity of 21.06%. The firm had revenue of $766.00 million for the quarter, compared to analysts’ expectations of $763.37 million.

Institutional Trading of Dr. Reddy’s Laboratories

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RDY. James Investment Research Inc. purchased a new position in shares of Dr. Reddy’s Laboratories during the 4th quarter worth about $29,000. CWM LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 24.0% in the 4th quarter. CWM LLC now owns 1,140 shares of the company’s stock valued at $59,000 after purchasing an additional 221 shares during the last quarter. Ronald Blue Trust Inc. grew its stake in shares of Dr. Reddy’s Laboratories by 43.2% during the 4th quarter. Ronald Blue Trust Inc. now owns 1,402 shares of the company’s stock valued at $73,000 after buying an additional 423 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 20.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,791 shares of the company’s stock worth $144,000 after buying an additional 483 shares during the last quarter. Finally, Janiczek Wealth Management LLC boosted its holdings in Dr. Reddy’s Laboratories by 7.8% in the fourth quarter. Janiczek Wealth Management LLC now owns 2,798 shares of the company’s stock valued at $149,000 after acquiring an additional 202 shares during the last quarter. Hedge funds and other institutional investors own 11.52% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

(Get Rating)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.

Read More

Earnings History and Estimates for Dr. Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.